Close Menu

Celgene

The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.

The collaboration will involve Evotec's Panomics platform, which integrates the analysis of genomic, transcriptomic, and proteomic data.


The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.

The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software. 

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.

The deal gives Celgene access to ImiDomics' database of genomic markers derived from biological samples for immune-mediated inflammatory diseases.

Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.

The partners aim to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve disease diagnosis, prognosis, and treatment.

Tempus will sequence and analyze pancreatic and melanoma cancer data from Penn patients to identify patterns associated with a positive response to treatment.

Pages

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.